Bioxyne Limited entered into an agreement to acquire Breathe Life Sciences Pty Ltd

Bioxyne Limited (ASX: BXN) announces that it has entered into a binding agreement with Breathe Life Sciences Pty Ltd. and its majority shareholders to buy Breathe Life Sciences Pty Ltd. The acquisition brings together the two direct sales leading companies in the food supplement, health, and wellness industry. Breathe Life Sciences is involved in developing plant-based products, including CBD-based therapies that promote health and wellness, and BXN deals in probiotics, dairy, and immune-based supplements.

This acquisition will increase the company’s product range and position the company as a global health and Wellness Company. The Breathe life Science and Bioxyne group will have operations in the following places: Asia Pacific, the United Kingdom USA, and Europe.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com